Expanding intellectual property:
Exploring novel mechanisms of action (MOA) and identifying new molecular targets and biomarkers for drug development.
From brain on a chip to clinic
Decode brain activity, predict drug efficacy, improve lives
A unique platform that integrates functional measurements from brain organoids with advanced AI analysis to estimate the efficacy of drugs for neurological and psychiatric disorders.
Rethinking drug development for better outcomes
In the realm of neurological and psychiatric disorders, traditional drug development methods are failing us. Animal models, particularly mice, often do not predict human outcomes accurately.
3.4 billion
People affected by neurological and psychiatric disorders globally
(43.1% of global population)
95%
Of drugs developed on mice fail in human clinical trials
5
New drugs
FDA-approved for neurological and psychiatric disorders in 20 years
<1%
Success rate in translating preclinical studies to clinical trials
Revolutionizing drug discovery:
The Itay&Beyond platform
Welcome to the future of neurological and psychiatric drug development –
where human-derived mini-brains meet cutting-edge AI.
Our innovative platform combines patient-derived brain organoids, advanced AI technology, and unparalleled functional readouts to break the deadlock
in drug discovery.
Patient-derived brain organoids
Miniature 3D replicas of human brains grown from patient cells, providing a more accurate model than traditional animal testing.
Functional
readouts
EEG-like measurements and other advanced techniques provide unprecedented insights into drug efficacy and brain function.
Drug efficacy prediction
Unparalleled drug and compound efficacy prediction based on electrophysiological readouts combined with advanced AI analysis.
Capabilities
Detection of abnormalities in organoids for precise analysis.
Drug testing and predictive modeling for effectiveness in correcting identified abnormalities.
Versatile platform adaptable to a broad spectrum of neuropsychiatric and neurological disorders.
Drug development process: applications for future therapies
Advancing drug development: from concept to market
Compound
screening
screening
Pre-clinic
Phase 1
Accurate drug efficacy predictions:
Early-stage accurate prediction of efficacy, before toxicity and safety studies.
Early-stage accurate prediction of efficacy, before toxicity and safety studies.
Phase 2
Phase 3
Study design optimization:
Improved evaluation of exclusion and inclusion criteria, to enhance the likelihood of successful outcomes.
Improved evaluation of exclusion and inclusion criteria, to enhance the likelihood of successful outcomes.
Post approval
marketing
marketing
Increasing revenue from approved compounds:
Repurposing and indication expansion to maximize the market potential of approved drugs.
Repurposing and indication expansion to maximize the market potential of approved drugs.
Compound screening
Pre-clinic / Phase 1
Phase 2 / Phase 3
Post approval marketing
Compound screening
Expanding intellectual property:
Exploring novel mechanisms of action (MOA) and identifying new molecular targets and biomarkers for drug development.
Pre-clinic / Phase 1
Accurate drug efficacy predictions:
Early-stage accurate prediction of efficacy, before toxicity and safety studies.
Phase 2 / Phase 3
Study design optimization:
Improved evaluation of exclusion and inclusion criteria, to enhance the likelihood of successful outcomes.
Post approval marketing
Increasing revenue from approved compounds:
Repurposing and indication expansion to maximize the market potential of approved drugs.
Pioneering autism research
Starting with low-functioning Autism disorders and expanding to other pathologies
Our groundbreaking work in autism, conducted in collaboration with Hadassah University Medical Center, showcases the power of our platform to revolutionize neurological research and drug development.
In our studies, we successfully distinguished between organoids derived from individuals with autism and those from neurotypical individuals. We also tested on additional pathologies such as epilepsy.
Our research is based on clinical samples from volunteers on the autism and neurodevelopmental spectrum. Contact us to check your eligibility for participation.
Our pipeline
Itay&Beyond revolutionizes neuropsychiatric drug discovery by combining brain organoids, dynamic brain function measurement, and AI analysis. Our platform predicts drug efficacy early in development, reducing failures in human trials and accelerating drug discovery. This approach offers new hope to millions affected by neurological and psychiatric disorders, providing an efficient path to developing treatments for a wide range of conditions.
About us
Itay&Beyond was founded by Mr. Shmulik Bezalel and inspired by his son Itay, who has Autism Spectrum Disorder (ASD). Recognizing the limited therapeutic options for neuropsychiatric disorders, Mr. Bezalel joined forces with Mr. Boaz Goldman and Dr. Nisim Perets to establish the company.
Our expert team
Led by pioneers in neuroscience and biotech, Itay&Beyond combines cutting-edge expertise with a passion for transforming lives.
Dr. Nisim Perets
Co-Founder and CEO
Dr. Nisim Perets
Distinguished neuroscientist with high-impact publications and innovative research in drug development.
Mr. Shmulik Bezalel
Co-Founder and Investor
Mr. Shmulik Bezalel
Visionary entrepreneur inspired by personal experience to revolutionize autism research.
Mr. Boaz Goldman
Co-Founder and Investor
Mr. Boaz Goldman
Seasoned entrepreneur and investor with a track record of nurturing groundbreaking technologies.
Dr. Nisim Perets
Co-Founder and CEO
Distinguished neuroscientist with high-impact publications and innovative research in drug development.
Mr. Shmulik Bezalel
Co-Founder and Investor
Visionary entrepreneur inspired by personal experience to revolutionize autism research.
Mr. Boaz Goldman
Co-Founder and Investor
Seasoned entrepreneur and investor with a track record of nurturing groundbreaking technologies.
Our advisory board
Dr. Ruth Tal-Singer
Former VP Innovation at Global GSK
Dr. Frida Grynspan
Head of Innovation Center at Lonza Israel
Arie Karmer
CEO Takeda Israel
Ronen Levi
Former CEO of Ministry of Foreign Affairs
Dr. Orit Shaked
Led the $110M investment in Pfizer
Prof. Ariel Tenenbaum
Head of Children’s Neurological Dept., Hadassah
Looking for partners to transform your drug development?
Ready to revolutionize your approach to drug discovery? Collaborate with us and harness cutting-edge technology to achieve more efficient, accurate, and ethical research.